000			03010cam a2200349 a 4500
003			EG-GiCUC
005			20250223031723.0
008			170514s2016 ua ho f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.08.08.Ph.D.2016.La.P
100	0		_aLamyaa Samir Ahmed Bazan
245	1	0	_aPreparation and evaluation of pH sensitive microparticles for colonic targeting / _cLamyaa Samir Ahmed Bazan ; Supervised Sabry Sayed Badawy , Omaima N. Elgazayerly , Ehab Rasmey Bendas
246	1	5	_aصياغة و تقييم جسيمات دقيقة تعتمد على التركيز الهيدروجينى لأستهداف القولون
260			_aCairo : _bLamyaa Samir Ahmed Bazan , _c2016
300			_a124 P. : _bfacsimiles , photographs ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aSpherical, uniform, smooth surfaced microparticles were successfully produced using emulsification / solvent evaporation process. The microparticles yield from the three polymers was above 80% with no significance difference between the three polymers (p<0.05). The microparticles using the three EUDRAGIT® polymers were capable of encapsulating celecoxib at high efficiency. The highest encapsulation efficiency was for EUDRAGIT® S100 followed by the other two polymers with no real difference between the three polymers. The high encapsulation efficiency and microparticle yield suggested that the process is efficient and economical at this scale. The prepared microparticles of the drug (F3, F6) reduced the inflammation and damage to the colon. This reduction was more when compared to that of the drug suspension and F9.The reduction of colon inflammation induced by acetic acid was really clear with EUDRAGIT® S100 and EUDRAGIT® L100-55 and to lesser extent EUDRAGIT® L100. Celecoxib reduced the severity of colonic injury induced by acetic acid and the prepared microparticles increased and localized the drug effect on the colon. The used LC MS/MS assay was specific and accurate to determine Celecoxib in rat plasma. The results obtained from the pharmacokinetic analysis suggested that the delay in Tmax indicated delayed release and slow release of the drug from the microparticles leading to the localization of the drug at the site of action which is the colon and may affect the extent of drug absorption. There was a clear increase in the bioavailability of celecoxib prepared as microparticles using the three EUDRAGIT® polymers
530			_aIssued also as CD
653		4	_aCelecoxib
653		4	_aColon targeting
653		4	_aPH dependent polymers
700	0		_aEhab Rasmey Bendas , _eSupervisor
700	0		_aOmaima N. Elgazayerly , _eSupervisor
700	0		_aSabry Sayed Badawy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c60886 _d60886